Pt(II) Complex with FGFR4 Specificity as a Targeted Drug Conjugate for the Treatment of Hepatocellular Carcinoma

View at publisher Summarise with VIRAT
Authors: Libo Cai, Gang Xu, Shaohua Gou
Cited by: 0
References: 44

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Hepatocellular carcinoma (HCC) is a highly refractory malignancy, for which treatment relies on molecule targeted therapy and/or conventional chemotherapy in clinic. However, these approaches generally suffer from limited efficacy or severe toxicity, restricting their applications. Guided by the targeted drug conjugate (TDC) strategy, the pharmacophore of lenvatinib was modified by incorporating DN604 (C 6 H 10 N 2 O 5 Pt), a carboplatin analogue, to generate a Pt(II) complex Len-604 (C 30 H 33 ClN 8 O 9 Pt). This compound was found to possess the specific capability to bind to fibroblast growth factor receptor 4 (FGFR4) protein both in vitro and in vivo, facilitating targeted delivery of DN604 to tumor sites and consequently triggering serious DNA damage in cancer cells. It exhibited potent cytotoxicity against human hepatocellular carcinoma cell lines HUH-7 and SMMC-7721, with IC 50 values of 5.62 and 5.64 μM, respectively. Significantly, in HUH-7 xenograft models, Len-604 exhibited stronger antitumor activity than lenvatinib, while showing lower toxicity than cisplatin and its physical mixture with lenvatinib.

Fields of Study & Subjects

Metal complexes synthesis and properties Radiopharmaceutical Chemistry and Applications Heterocyclic Compound Synthesis and Bioactivity

Publication details

Journal / source
Inorganic Chemistry
Volume
65
Issue
14
Pages
7833–7847
Publication date
30 March 2026
Language
EN